Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? (Q47907594)

6 February 2018

title

Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? (English)

1 reference

6 February 2018

author name string

Guilherme Godoy

series ordinal

1

1 reference

6 February 2018

Basir U Tareen

series ordinal

2

1 reference

6 February 2018

Herbert Lepor

series ordinal

3

1 reference

6 February 2018

language of work or name

English

0 references

publication date

5 May 2009

1 reference

6 February 2018

published in

Urology

1 reference

6 February 2018

volume

74

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

167-170

1 reference

6 February 2018

Residual benign prostatic glands at the urethrovesical anastomosis after radical retropubic prostatectomy: prediction and impact on disease outcome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Does urethral-sparing prostatectomy risk residual prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

THE ROLE OF BLADDER NECK BIOPSY IN MEN UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY WITH PRESERVATION OF THE BLADDER NECK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Incidence of Benign and Malignant Prostate Tissue in Biopsies of Bladder Neck After a Radical Prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Benign positive margins after radical prostatectomy means a poor prognosis--pro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Radical retropubic prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Optimizing patient selection for prostate monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Prognostic Significance of Location of Positive Margins in Radical Prostatectomy Specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.07.067

10.1016/J.UROLOGY.2008.07.067

7 January 2021

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018